Thiogenesis Therapeutics, Corp. TTI
Updated: 14 Jun 2026
No signal published yet
We already track Thiogenesis Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Thiogenesis Therapeutics, Corp.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Thiogenesis Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 3, 2026, the company closed an oversubscribed private placement raising approximately 9.07 million CAD in gross proceeds. The capital will be used to advance clinical development of TTI-0102, including a Phase 2a study in Leigh syndrome and an investigator-initiated study in cystinosis.
What Firelda Watch includes for Thiogenesis Therapeutics, Corp.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Thiogenesis Therapeutics, Corp.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Thiogenesis Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more